Tisagenlecleucel for Treatment of Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia (R/R B-All): A Systematic Review of Cost-Effectiveness Analysis

VNU Journal of Science: Medical and Pharmaceutical Sciences Pub Date : 2024-04-16 DOI:10.25073/2588-1132/vnumps.4582

Phung Thao Nguyen, Ha Van Thuy, Bui Thi Xuan

{"title":"Tisagenlecleucel for Treatment of Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia (R/R B-All): A Systematic Review of Cost-Effectiveness Analysis","authors":"Phung Thao Nguyen, Ha Van Thuy, Bui Thi Xuan","doi":"10.25073/2588-1132/vnumps.4582","DOIUrl":null,"url":null,"abstract":"Tisagenlecleucel is a new immunological therapy in refractory or relapsed B-cell lymphoblastic leukemia with high expense. Objective: To assess the quality as well as analyze characteristics and results of cost-effectiveness analysis (CEA) of tisagenlecleucel immunological therapy in children with R/R B-ALL. Method: To analyze systematic review of articles published during the period of 2017-2023 in Pubmed, ScienceDirect, GoogleScholar, Cochrane databases. Result: 10 selected studies were carried out in 8 nations with different cost units and discount rates. Compared therapies were standard therapy of each country included Blinatumomab, Clo-C, Clo-M, FLA-IDA, FLAG-IDA. Of 10 studies, 70% was considered cost-effectiveness, 20% non-conclusion and only 10% not cost-effectiveness. Conclusion: Tisagenlecleucel’s cost is the highest among compared therapies but it can be cost-effective in a nation with WTP threshold of $100.000-$150.000. \nKeywords: Systematic review, cost-effective, tisagenlecleucel, CAR-T, acute lymphoblastic leukemia. \n \n ","PeriodicalId":23520,"journal":{"name":"VNU Journal of Science: Medical and Pharmaceutical Sciences","volume":"14 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"VNU Journal of Science: Medical and Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25073/2588-1132/vnumps.4582","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Tisagenlecleucel is a new immunological therapy in refractory or relapsed B-cell lymphoblastic leukemia with high expense. Objective: To assess the quality as well as analyze characteristics and results of cost-effectiveness analysis (CEA) of tisagenlecleucel immunological therapy in children with R/R B-ALL. Method: To analyze systematic review of articles published during the period of 2017-2023 in Pubmed, ScienceDirect, GoogleScholar, Cochrane databases. Result: 10 selected studies were carried out in 8 nations with different cost units and discount rates. Compared therapies were standard therapy of each country included Blinatumomab, Clo-C, Clo-M, FLA-IDA, FLAG-IDA. Of 10 studies, 70% was considered cost-effectiveness, 20% non-conclusion and only 10% not cost-effectiveness. Conclusion: Tisagenlecleucel’s cost is the highest among compared therapies but it can be cost-effective in a nation with WTP threshold of $100.000-$150.000. Keywords: Systematic review, cost-effective, tisagenlecleucel, CAR-T, acute lymphoblastic leukemia.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

治疗难治或复发 B 细胞急性淋巴细胞白血病（R/R B-All）的 Tisagenlecleucel：成本效益分析系统综述

Tisagenlecleucel 是一种治疗难治或复发 B 细胞淋巴细胞白血病的新型免疫疗法，费用较高。目的评估 Tisagenlecleucel 免疫疗法在 R/R B-ALL 儿童中的质量，并分析其特点和成本效益分析（CEA）结果。方法对Pubmed、ScienceDirect、GoogleScholar、Cochrane数据库中2017-2023年间发表的文章进行系统回顾分析。结果：所选的10项研究在8个国家进行，采用不同的成本单位和贴现率。比较的疗法为各国的标准疗法，包括Blinatumomab、Clo-C、Clo-M、FLA-IDA、FLAG-IDA。在 10 项研究中，70% 被认为具有成本效益，20% 未得出结论，只有 10% 不具有成本效益。结论Tisagenlecleucel 的成本是所有疗法中最高的，但在 WTP 临界值为 100.000-150.000 美元的国家，它是具有成本效益的。关键词系统综述成本效益 Tisagenlecleucel CAR-T 急性淋巴细胞白血病

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

VNU Journal of Science: Medical and Pharmaceutical Sciences

自引率

0.00%

发文量